AstraZeneca says a new COVID drug could guard against all variants of concern to date.
A replacement for a key COVID-19 antibody drug that has been used to protect immunocompromised Americans could be available within months, executives for drugmaker AstraZeneca said Thursday, after promising early results suggested it may work against"all known variants of concern" to date."Supernova"
"In vitro studies demonstrated that AZD3152 neutralizes all COVID-19 variants, including Arcturus, the latest variant of concern," AstraZeneca's Mene Pangalos told investors on anAstraZeneca says the drug could benefit some 2% of the population who cannot mount an effective immune response from COVID-19 vaccines.
AstraZeneca says its new AZD3152 drug is based on a different antibody – derived from donated B cells of people who have recovered from infections – and it is"designed to have broader variant coverage" than Evusheld for six months.with COVID-19 antiviral drugs, like Pfizer's Paxlovid or Gilead's Veklury treatments. However, these drugs can sometimes lead to the virus only being suppressed – but not eliminated – in immunocompromised patients.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AstraZeneca beats estimates on strong emerging market sales as COVID wanesAstraZeneca on Thursday beat expectations for first-quarter profit and revenue, as buoyant sales of cancer drug Imfinzi and strong demand for its roster of drugs in emerging markets helped to offset dwindling COVID product sales.
Read more »
FDA Gives Fast-Track Approval to New ALS DrugThe FDA fast-tracked the approval on the basis of early trial results.
Read more »
FDA approves Biogen's drug for rare form of ALSThe U.S. Food and Drug Administration has approved a new drug to treat a rare form of Amyotrophic Lateral Sclerosis (ALS), also commonly known as Lou Gehrig’s disease.
Read more »
Dogs can join owners for outdoor dining, FDA saysThe FDA updated its food policy earlier this year to let owners and their furry friends enjoy eating together.
Read more »
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief saysMedicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis.
Read more »
Don't use 'amniotic fluid' eye drops, FDA warns'Amniotic fluid' eye drops aren't approved and could be harmful, the Food and Drug Administration warned.
Read more »